A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a new study.

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional ...

50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA ...

Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” third quarter 2024 investor ...

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third quarter ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings! And welcome to the DURECT Corporation Third Quarter ...

Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† ...

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...